drugset / Trial / NCT05508737
Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a two-part, Phase II, open-label, single arm, multi-center study to determine the efficacy of pembrolizumab in combination with TAS-102 (trifluridine/tipiracil) in patients with advanced gastric cancer who have progressed after prior treatment with or without anti-PD-1/PD-L1 agent, and to further assess the safety and tolerability of this combination treatment.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2025-11-02
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Trifluridine/Tipiracil | Unknown | 30 mg/m2 | — |
| Subject | Trifluridine/Tipiracil | Unknown | 35 mg/m2 | — |